MAP2K7 and rheumatoid arthritis: Our previous work [14,34,35] has successfully shown that targeting MAPK at TNF receptor-associated factor 6-mitogen-activated protein kinase 7 (TRAF6-TAK1) signalosome in rheumatoid arthritis synovial fibroblasts using EGCG effectively curbs the IL-1 induced IL-6 production.